Zhejiang Huahai Pharmaceutical saw the highest growth of 1.66% in patent filings in June and 1.49% in grants in May in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.59% and grants by 0.66%. GlobalData’s DataBook provides a comprehensive analysis of Zhejiang Huahai Pharmaceutical‘s patent filings and grants. Buy the databook here.
Zhejiang Huahai Pharmaceutical has been focused on protecting inventions in China(CN) with six publications in Q2 2024
The China(CN) Patent Office dominates the patent filings and grants with nearly 27% filings and 50% grants. The World Intellectual Property Organization(WIPO), China(CN), European Patent Office(EPO), and Australia(AU) patent Office are among the top ten patent offices where Zhejiang Huahai Pharmaceutical is filings its patents. Among the top granted patent authorities, Zhejiang Huahai Pharmaceutical has 50% of its grants in China(CN), 17% in European Patent Office(EPO) and 17% in Australia(AU).
Roche and Johnson & Johnson could be the strongest competitors for Zhejiang Huahai Pharmaceutical
Patents related to addiction and climate change lead Zhejiang Huahai Pharmaceutical's portfolio
Zhejiang Huahai Pharmaceutical has the highest number of patents in addiction followed by, climate change. For addiction, nearly 100% of patents were filed and no patents were granted in Q2 2024.
Manufacturing/industrial related patents lead Zhejiang Huahai Pharmaceutical portfolio
Zhejiang Huahai Pharmaceutical has highest number of patents in manufacturing/industrial.
For comprehensive analysis of Zhejiang Huahai Pharmaceutical's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.